Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 40 studies | 51% ± 19% | |
pericyte | 27 studies | 42% ± 19% | |
smooth muscle cell | 25 studies | 49% ± 18% | |
endothelial cell of lymphatic vessel | 21 studies | 52% ± 16% | |
basal cell | 20 studies | 41% ± 17% | |
endothelial cell | 19 studies | 33% ± 14% | |
ciliated cell | 16 studies | 48% ± 14% | |
connective tissue cell | 15 studies | 53% ± 17% | |
macrophage | 14 studies | 26% ± 11% | |
epithelial cell | 13 studies | 40% ± 21% | |
myofibroblast cell | 12 studies | 54% ± 16% | |
secretory cell | 10 studies | 39% ± 17% | |
endothelial cell of vascular tree | 10 studies | 39% ± 15% | |
alveolar macrophage | 8 studies | 45% ± 20% | |
type I pneumocyte | 8 studies | 50% ± 13% | |
type II pneumocyte | 8 studies | 61% ± 25% | |
abnormal cell | 8 studies | 36% ± 21% | |
astrocyte | 8 studies | 35% ± 17% | |
club cell | 6 studies | 37% ± 14% | |
capillary endothelial cell | 6 studies | 25% ± 9% | |
goblet cell | 6 studies | 32% ± 12% | |
respiratory goblet cell | 5 studies | 27% ± 10% | |
mesothelial cell | 5 studies | 29% ± 10% | |
vein endothelial cell | 5 studies | 25% ± 10% | |
intestinal crypt stem cell | 5 studies | 36% ± 15% | |
transit amplifying cell | 5 studies | 34% ± 8% | |
adventitial cell | 4 studies | 70% ± 11% | |
endothelial cell of artery | 4 studies | 19% ± 5% | |
mucus secreting cell | 4 studies | 53% ± 28% | |
myeloid cell | 4 studies | 29% ± 7% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 53% ± 10% | |
adipocyte | 4 studies | 31% ± 19% | |
hepatocyte | 4 studies | 53% ± 31% | |
luminal cell of prostate epithelium | 4 studies | 53% ± 8% | |
keratinocyte | 4 studies | 51% ± 18% | |
deuterosomal cell | 3 studies | 19% ± 0% | |
hillock cell | 3 studies | 36% ± 10% | |
microglial cell | 3 studies | 32% ± 7% | |
epithelial cell of proximal tubule | 3 studies | 40% ± 13% | |
placental villous trophoblast | 3 studies | 36% ± 13% | |
retinal pigment epithelial cell | 3 studies | 41% ± 21% | |
serous secreting cell | 3 studies | 65% ± 11% | |
Mueller cell | 3 studies | 52% ± 9% | |
muscle cell | 3 studies | 31% ± 16% | |
Schwann cell | 3 studies | 44% ± 19% | |
progenitor cell of mammary luminal epithelium | 3 studies | 29% ± 1% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 36% ± 13% | |
intestine | 8 studies | 22% ± 6% | |
uterus | 6 studies | 32% ± 11% | |
prostate | 5 studies | 31% ± 9% | |
breast | 4 studies | 35% ± 5% | |
liver | 4 studies | 21% ± 7% | |
skin | 4 studies | 37% ± 18% | |
placenta | 3 studies | 28% ± 8% | |
ovary | 3 studies | 39% ± 15% | |
esophagus | 3 studies | 32% ± 5% | |
eye | 3 studies | 30% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 11641.00 | 245 / 245 | 100% | 15.98 | 500 / 502 |
breast | 100% | 10290.29 | 459 / 459 | 91% | 6.59 | 1019 / 1118 |
liver | 100% | 9709.55 | 225 / 226 | 90% | 8.26 | 365 / 406 |
ovary | 100% | 9028.99 | 180 / 180 | 89% | 7.14 | 381 / 430 |
kidney | 96% | 3870.37 | 85 / 89 | 90% | 7.12 | 815 / 901 |
thymus | 100% | 20452.74 | 652 / 653 | 72% | 6.14 | 433 / 605 |
pancreas | 100% | 11991.68 | 327 / 328 | 70% | 3.01 | 124 / 178 |
uterus | 100% | 8849.14 | 170 / 170 | 68% | 4.21 | 313 / 459 |
lung | 100% | 9161.15 | 577 / 578 | 64% | 3.12 | 734 / 1155 |
esophagus | 100% | 8072.68 | 1444 / 1445 | 62% | 3.60 | 114 / 183 |
skin | 100% | 9973.96 | 1807 / 1809 | 59% | 3.40 | 277 / 472 |
stomach | 96% | 5394.12 | 346 / 359 | 62% | 3.99 | 176 / 286 |
brain | 72% | 2498.42 | 1890 / 2642 | 85% | 4.85 | 598 / 705 |
intestine | 96% | 8540.97 | 927 / 966 | 54% | 3.54 | 286 / 527 |
bladder | 100% | 10539.43 | 21 / 21 | 44% | 2.62 | 222 / 504 |
adrenal gland | 100% | 13181.18 | 258 / 258 | 33% | 2.55 | 76 / 230 |
adipose | 100% | 9644.76 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 9178.61 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 15.20 | 80 / 80 |
heart | 82% | 3019.52 | 705 / 861 | 0% | 0 | 0 / 0 |
muscle | 81% | 4358.39 | 648 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 76% | 3.76 | 34 / 45 |
spleen | 62% | 1535.23 | 150 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 59% | 2.66 | 17 / 29 |
peripheral blood | 1% | 36.44 | 9 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0062099 | Biological process | negative regulation of programmed necrotic cell death |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_1901800 | Biological process | positive regulation of proteasomal protein catabolic process |
GO_0045786 | Biological process | negative regulation of cell cycle |
GO_0048147 | Biological process | negative regulation of fibroblast proliferation |
GO_1905897 | Biological process | regulation of response to endoplasmic reticulum stress |
GO_1904691 | Biological process | negative regulation of type B pancreatic cell proliferation |
GO_2001244 | Biological process | positive regulation of intrinsic apoptotic signaling pathway |
GO_0042771 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0002526 | Biological process | acute inflammatory response |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0050680 | Biological process | negative regulation of epithelial cell proliferation |
GO_0031401 | Biological process | positive regulation of protein modification process |
GO_0043525 | Biological process | positive regulation of neuron apoptotic process |
GO_0065003 | Biological process | protein-containing complex assembly |
GO_0045820 | Biological process | negative regulation of glycolytic process |
GO_2000271 | Biological process | positive regulation of fibroblast apoptotic process |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0010506 | Biological process | regulation of autophagy |
GO_0048144 | Biological process | fibroblast proliferation |
GO_1904036 | Biological process | negative regulation of epithelial cell apoptotic process |
GO_1902902 | Biological process | negative regulation of autophagosome assembly |
GO_0010507 | Biological process | negative regulation of autophagy |
GO_0008584 | Biological process | male gonad development |
GO_0150078 | Biological process | positive regulation of neuroinflammatory response |
GO_0010667 | Biological process | negative regulation of cardiac muscle cell apoptotic process |
GO_0035914 | Biological process | skeletal muscle cell differentiation |
GO_0009636 | Biological process | response to toxic substance |
GO_1903862 | Biological process | positive regulation of oxidative phosphorylation |
GO_2000194 | Biological process | regulation of female gonad development |
GO_0044346 | Biological process | fibroblast apoptotic process |
GO_0045787 | Biological process | positive regulation of cell cycle |
GO_0032993 | Cellular component | protein-DNA complex |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005654 | Cellular component | nucleoplasm |
GO_0045171 | Cellular component | intercellular bridge |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0010698 | Molecular function | acetyltransferase activator activity |
GO_0003677 | Molecular function | DNA binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NUPR1 |
Protein name | Nuclear protein 1 (Candidate of metastasis 1) (Protein p8) Nuclear protein 1, transcriptional regulator |
Synonyms | COM1 |
Description | FUNCTION: Transcription regulator that converts stress signals into a program of gene expression that empowers cells with resistance to the stress induced by a change in their microenvironment. Thereby participates in regulation of many process namely cell-cycle, apoptosis, autophagy and DNA repair responses . Controls cell cycle progression and protects cells from genotoxic stress induced by doxorubicin through the complex formation with TP53 and EP300 that binds CDKN1A promoter leading to transcriptional induction of CDKN1A . Protects pancreatic cancer cells from stress-induced cell death by binding the RELB promoter and activating its transcription, leading to IER3 transactivation . Negatively regulates apoptosis through interaction with PTMA . Inhibits autophagy-induced apoptosis in cardiac cells through FOXO3 interaction, inducing cytoplasmic translocation of FOXO3 thereby preventing the FOXO3 association with the pro-autophagic BNIP3 promoter . Inhibits cell growth and facilitates programmed cell death by apoptosis after adriamycin-induced DNA damage through transactivation of TP53 (By similarity). Regulates methamphetamine-induced apoptosis and autophagy through DDIT3-mediated endoplasmic reticulum stress pathway (By similarity). Participates in DNA repair following gamma-irradiation by facilitating DNA access of the transcription machinery through interaction with MSL1 leading to inhibition of histone H4' Lys-16' acetylation (H4K16ac) . Coactivator of PAX2 transcription factor activity, both by recruiting EP300 to increase PAX2 transcription factor activity and by binding PAXIP1 to suppress PAXIP1-induced inhibition on PAX2 . Positively regulates cell cycle progression through interaction with COPS5 inducing cytoplasmic translocation of CDKN1B leading to the CDKN1B degradation . Coordinates, through its interaction with EP300, the assiociation of MYOD1, EP300 and DDX5 to the MYOG promoter, leading to inhibition of cell-cycle progression and myogenic differentiation promotion . Negatively regulates beta cell proliferation via inhibition of cell-cycle regulatory genes expression through the suppression of their promoter activities (By similarity). Also required for LHB expression and ovarian maturation (By similarity). Exacerbates CNS inflammation and demyelination upon cuprizone treatment (By similarity). . |
Accessions | ENST00000567646.1 H3BS92 ENST00000395641.2 [O60356-2] O60356 ENST00000324873.8 [O60356-1] |